Vertex Pharmaceuticals Announced Positive Results from its Non-Opioid Product VX-548

Vertex Pharmaceuticals Positive Results for VX-548
Today, Vertex Pharmaceuticals (VRTX) announced positive results from its Phase 3 program for the treatment of moderate-to-severe acute pain. The Phase 3 program included two randomized, double- blind, placebo-controlled, pivotal trials, one following abdominoplasty . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.